New Research Indicates that Happiness Powered by Autonomy During Pandemic is Crucial to Good Employee Performance

EDINBURGH, SCOTLAND / ACCESSWIRE / July 28, 2020 / New, world-leading research from Identity Realization demonstrates that whether working from home or the changing, Covid-19 office; the key to good performance – and the key to success for every business – is ‘happiness' powered by employee autonomy.

Running a survey and an experiment titled, "Covid-19: The Value of a Creative Culture," Identity Realization enquired about the population's emotional and mental temperature, and its intellectual performance as people contemplated a return to workplace. The project explored the upsides of working from home and the elements of the old workplace that employees were missing, as well as the psychological effects of Covid-19 on feelings, performance and function.

During lockdown, a happy employee was seen to be autonomous, and connected to both friends and colleagues. Pandemic notwithstanding, these psychological engines delivered a strong sense of wellness. This in turn, meant better engagement across the organization, less stress, higher feelings of creativity and sustained performance. Unhappy workers, meanwhile, suffered across all fronts including their noticeably inferior intellectual performance.

"Our research found that organizations should allow conversations, stop monitoring and allow autonomy; all of which results in a happy and engaged employee," said Dr. Craig Knight, Founder of Identity Realization who is a Chartered Psychologist with the British Psychological Society, and Registered Occupational Psychologist with the Health and Care Professions Council, as well as an Honorary Research Fellow at The University of Exeter. "The results of the research were dramatic and found that happiness is engendered by a combination of active social and business connections, and of being allowed to manage the work flow as the employee saw fit."

In a connected experiment exploring colour, respondents working on a quiz with a red background performed significantly worse than colleagues doing the same quiz on a white or blue background.

"Autonomous, connected workers felt more psychologically comfortable when doing their jobs with reduced stress, better engagement at all levels of the organization, higher feelings of creativity and sustained levels of performance," adds Dr. Knight. "Unhappy workers, meanwhile, suffered across all fronts including their intellectual performance which was significantly worse than their happier peers."

"Nobody needs a pool table or ‘happy hour' at the office," says Dr. Knight. "The research indicates that what they do need is trust from their employer, meaningful contact with others and freedom of choice."

Survey Details

The survey was issued to people who were working at home as a result of the Coronavirus lockdown imposed in March 2020 on the Work Mind platform. Survey responses were collected from June 24th to July 4th 2020 when lockdown restrictions were beginning to lift which allowed employees to be assessed about lockdown and ahead to the new, uncertain world unfolding before them.

The survey queried 124 people from the United Kingdom, North America and Australia with a median age of 41.6 years old.

This research conducted by Dr. Craig Knight, Identity Realization, was commissioned by Catherine Thomas of Art Acumen in consultation with Zefa Mongan of The Future Collective and supported by Obo Life, workplace advisors. Dr. Knight has been investigating how to improve the lives of people at work since 2003. His work has been published globally and he has appeared in print and on television around the globe.

Performance Data

The data was split in terms of happiness. The happiness scale is the average of all positively scored answers across the entire survey. In the "Covid-19: The Value of a Creative Culture" survey, 24% of people were unhappy, scoring under 50/100 on the scale; 48% were OK (50-70/100) and the remaining 28% classified as happy.

"The key variables that management and organizations can control or encourage are autonomy and strength of networks with friends and colleagues," says Dr. Knight. "Compared to their happy counterparts, unhappy people felt that their networks were 67% weaker. Their levels of autonomy were 70% reduced. These data are directly linked with a sense of wellness (or psychological comfort) that is 62% lower for unhappy people."

In turn wellness is associated with stress where happy employees have 30% lower levels of stress, claim to be 66% more altruistic (which means going beyond the bounds of their contract for no extra pay, and helping others even at personal risk) and an extraordinary 177% more creative.

Meanwhile, unhappy people have largely disengaged from their organizations, their peers and even their country with levels down by 52%, 57% and 70% respectively compared to happier peers. Perhaps most significantly, happy staff performed at a level that was 38% better than their unhappy peers. The implications for an organization's bottom line are stark.

"There was no significant difference across our variables at all in terms of age, gender, or position on the organizational hierarchy," adds Dr. Knight. "For example, the idea that Millennials would be more miserable than Boomers was just not supported."

About Identity Realization Limited:

Based in Scotland, Identity Realization Limited (IDR), was founded by Dr. Craig Knight and established at the University of Exeter in 2003 to explore and develop business design, change management and leadership. IDR's evidence-based work develops an identity centered, psychological approach to improving organizational effectiveness. IDR's focus is on evidence-based leadership, management and employee retention.

# # #

Media Contacts:

U.S. Contact: Nancy Thompson, Vorticom, Inc.
212.532.2208,
nancyt@vorticom.com

U.K. Contact: Anna King, Informare:PR
212.532.2208,
+ 44 (0) 7780 956291
anna@informare.co.uk

SOURCE: Identity Realization

ReleaseID: 598802

Kore.ai Acknowledged for Helping Enterprise Customers Drive Their Digital Transformation via Blue Prism's Digital Workforce

LONDON, UK, AUSTIN, TX and ORLANDO, FL / ACCESSWIRE / July 28, 2020 / Last month at Blue Prism World Virtual 2020, Kore.ai received an award for its excellence in delivering Blue Prism's connected-RPA offering. These awards acknowledge the key partners in Blue Prism's ecosystem while showcasing their expertise in delivering intelligent automation capabilities to digitally transform how organizations operate, compete, and innovate.

"We've built a true community of intelligent automation pioneers, innovators, developers and doers at Blue Prism," says Linda Dotts, Chief Partner Strategy Officer for Blue Prism. "This community is our lifeblood, which enables us to deliver one the most versatile and successful digital workforces on the planet. Congratulations to Kore.ai for showing us what's possible and for making Blue Prism truly the sum of our parts."

"We're truly honored," says Robin Kearon, SVP Channel and Alliances at Kore.ai. "This recognition proves that Artificial Intelligence (AI)-powered conversation offers a powerful way to elevate how business processes are executed. Kore.ai's Virtual Assistants and Blue Prism's Digital Workers are extending the boundaries of customer service and delighting employees and customers in a way that has not been seen before. Particularly, Blue Prism's connected-RPA approach is aligned to our own philosophy of building intelligent enterprises."

Kore.ai-Blue Prism partnership integrates two market-leading platforms to deliver end-to-end automation capabilities, supporting companies in diverse verticals such as Financial Services, Healthcare, Insurance, Retail and various cross-industry processes for Customer Care, Vendor Support, HR Onboarding and more, as they transform to digital enterprise and gain market advantage.

About Blue Prism

Blue Prism's vision is to provide a Digital Workforce for Every Enterprise. The company's purpose is to unleash the collaborative potential of humans, operating in harmony with a Digital Workforce, so every enterprise can exceed their business goals and drive meaningful growth, with unmatched speed and agility.

Fortune 500 and public-sector organizations, among customers across 70 commercial sectors, trust Blue Prism's enterprise-grade connected-RPA platform, which has users in more than 170 countries. By strategically applying intelligent automation, these organizations are creating new opportunities and services, while unlocking massive efficiencies that return millions of hours of work back into their business.

Available on-premises, in the cloud, hybrid, or as an integrated SaaS solution, Blue Prism's Digital Workforce automates ever more complex, end-to-end processes that drive a true digital transformation, collaboratively, at scale and across the entire enterprise.

Visit www.blueprism.com to learn more or follow Blue Prism on Twitter @blue_prism and on LinkedIn.

About Kore.ai

Kore.ai is a market-leading Conversational AI and Digital UX Technology Partner for Global 2000 companies. It provides Conversational AI and Digital UX-rich Virtual Assistants, designed specifically for enterprises, for a diverse range of use cases across industries for engaging customers, employees and partners. Its end-to-end, comprehensive Virtual Assistant Platform serves as a secure foundation for enterprises to design, build, test, host and deploy AI-rich virtual assistants across 30+ different Digital and Voice channels. Kore.ai also provides Enterprise Virtual Assistants, pre-trained and pre-built Virtual Assistants for Banking, HR and IT HelpDesk. Kore.ai partners with top ISVs and global system integrators for helping companies meet their digital transformation needs.

Kore.ai has repeatedly won global analyst acclaim and has been positioned as a Leader in Everest Group's ‘Intelligent Virtual Agents – Technology Vendor Landscape with Products PEAK Matrix® Assessment 2020', Gartner Market Guide 2019 for Conversational Platforms, Gartner Market Guide for Virtual Customer Assistants 2019, and IDC Innovators: Conversational AI Software Platforms 2018, among others. Visit kore.ai to learn more.

Media Contacts

Andre Fuochi

Blue Prism

Mobile: +1 469-394-7274

andre.fuochi@blueprism.com

Karthik G

Kore.ai

Mobile: +91 97019 26120

karthik.gandrajupalli@kore.com

© 2020 Blue Prism Limited. "Blue Prism", "Thoughtonomy", the "Blue Prism" logo and Prism device are either trademarks or registered trademarks of Blue Prism Limited and its affiliates. All Rights Reserved.

SOURCE: Kore.ai

ReleaseID: 598992

VANCOUVER, BC / ACCESSWIRE / July 28, 2020 / Brains Bioceutical Corp (Brains) is proud to announce it and Cronos Australia Limited (Cronos Australia) have entered into a Supply Agreement pursuant to which Brains has been selected as a strategic supplier of CBD products to Cronos Australia for distribution in Australia. Under this strategic partnership, Brains will utilize its patent pending industry leading scientific data package for its plant based Active Pharmaceutical Ingredient "API" cannabidiol "CBD" molecule to assist Cronos Australia register and gain approval from the Australian Therapeutics Goods Administration on finished medicinal cannabinoid products. Brains will provide Cronos Australia with finished CBD products manufactured with the "Brains Inside" Brains Pure CBD kitemark of quality.

This partnership adds to Brains strategic global footprint. The company has successfully shipped to over 10 countries around the world including Germany, USA, Austria, Brazil, Australia and most recently to a New Zealand crown corporation for research and testing. Brains supplies their API to select clinical trials in Australia at the Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, and The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE).

"To be partnering with companies such as Cronos Australia, we are able to continue advancing our contract manufacturing partner relationships which strengthens our global reach and is expected to contribute to improved revenues in the future," commented Ricky Brar, CEO & Chairman of Brains Bioceutical Corp, "we are very excited to build out our strategic platform in Australia, in partnership with Rodney and his team at Cronos Australia".

Cronos Australia has partnered with Brains as a result of it being one of the few companies in the world with the ability to produce EUGMP certified, plant-based CBD, as an Active Pharmaceutical Ingredient ("API") at commercial volumes. Currently, Brains is one of the largest commercial manufacturers of EUGMP CBD API in the world, and due to global demand, Brains is currently expanding its Pfizer Discovery Park facility in Sandwich Kent UK to increase production of CBD and other EUGMP certified Cannabinoids. Brains is one of the leading global research and development companies with respect to CBD, and its experienced Science and Pharma teams were able to navigate the Australian mandate in a hyper-efficient way. Brains has received initial purchase orders and a deposit from Cronos Australia and will start with producing CBD oil, with all formulation, preparation, and packaging procedures performed in compliance with applicable regulations.

"As the market continues to evolve in Australia, we believe Brains brings value to our patients through their proprietary extraction and formulation expertise and industry leading quality with an API designation for the CBD" commented Rodney Cocks, CEO of Cronos Australia. "We are pleased to be partnering with Brains on the launch of our ‘Adaya' product line".

About Brains Bioceutical Corp:

Brains Bioceutical Corp is a global leader in pharmaceutical, wellness, athletics and veterinary cannabidiol (CBD) based Active Pharmaceutical Ingredient (API) production for commercial use. Our roots lie in nature, the place where exceptional is found. We are one of nine companies in the world to possess the API designation for CBD under Eudra GMPD and one of three in the world certified to produce from a natural, plant-based source. Our CBD API product lines are THC-free, non-GMO and produced in our wholly-owned BSPG Laboratories in the UK. Forever advancing and enriching, Brains is involved in international clinical trials, including a phase 3, double-blind clinical trial using CPB API for treatment of refractory epilepsy, exclusively supplied by Brains Bioceutical. ALTIS / Brains Bioceutical Living Lab, a state-of-the-art, interdisciplinary athletics training facility, explores, experiments, and evaluates the power of CBD API in elite athletes. Under the strategic leadership of our co-founder, Chairman & CEO Ricky Brar and with a rare hybrid of pharmaceutical and consumer goods senior executives, the Brains Bioceutical Team works with the science of nature, never against it, extracting its power to help make better.

About Cronos Australia

Cronos Australia Limited was established as a 50:50 joint venture between global cannabinoid company Cronos Group Inc (dual-listed — NASDAQ: CRON, TSX: CRON) and NewSouthern Capital. The Company was formed to accelerate growth and capture opportunities relating to the emerging cannabis industry both domestically and internationally. The vision of Cronos Australia is to become a leading health and wellness company in the Asia Pacific region through the distribution of premium cannabis products.

CAUTIONARY STATEMENT: This news release contains forward looking statements or forward-looking information ("forward-looking statements") within the meaning of securities laws. Often, but not always, forward looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. All statements, other than statements of historical fact, in this news release are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. Risks, uncertainties and other factors involved with forward-looking statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, there can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

CONTACT:

Calvin Rasode,
Director of Marketing
1-855-927-2476
calvin@brainsbio.com
www.brainsbio.com

SOURCE: Brains Bioceutical Corp

ReleaseID: 599094

HOUSTON, TX / ACCESSWIRE / July 28, 2020 / ​​Memgen, Inc., a private biotechnology company developing innovative immune-based drugs for the control of infectious diseases and cancer, announced today that Dr. Thomas Monath, a world-renowned virologist and vaccinologist, has joined the Company's Scientific Advisory Board. The addition of Dr. Monath highlights the potential of the Company's vaccine program as it advances its COVID-19 vaccine candidate to the clinic.

Dr. Monath, Managing Partner and Chief Scientific Officer of Crozet Biopharma, has worked in leadership positions in US government agencies and in the biotechnology sector, and had primary responsibility for bringing multiple innovative vaccines into clinical development, including Ebola Zaire, cell-based smallpox, dengue, Japanese encephalitis, West Nile, cytomegalovirus, influenza, live and inactivated yellow fever, Helicobacter pylori, and Clostridium difficile, four of which are now licensed and commercialized.

In addition to Memgen, Tom serves on the boards of Juvaris Inc., Sentinext Plc, and US Biologic Inc. and on the Scientific Advisory Boards of RapidMicro Biosystems, GeoVax and SutroVax. Between 2006-2012, Dr. Monath was a Partner at Kleiner Perkins Caufield & Byers, a leading venture capital firm where he oversaw investments in the vaccine space. Before joining the industry, Dr. Monath served in the uniformed services of US Public Health Service and the US Army, retiring as a Colonel. During that time, he was Director, Division of Vector-Borne Viral Diseases at the Centers for Disease Control and Prevention (CDC) and Chief, Virology Division at the US Army Medical Research Institute of Infectious Diseases (USAMRIID).

Tom received his AB degree from Harvard College and his MD from Harvard Medical School and is board-certified in internal medicine. He has received many prestigious awards, including the Nathanial A. Young Award, the Richard M. Taylor Award, the Walter Reed Medal and the James H. Steele Award. He has served on numerous government and international committees on infectious diseases, biosecurity, WHO expert committees and the National Vaccines Advisory Committee (USA), and is Past-President of the American Society of Tropical Medicine and Hygiene and an elected Fellow of the Society. He has published over 425 scientific papers and 6 books on virology and vaccine development and has 35 patents.

Dr. Monath noted, "I am pleased and excited to join the Scientific Advisory Board of Memgen. The Company's novel CD40 ligand technology offers differentiated potential as an immune stimulant and vaccine adjuvant, and I look forward to working with the company to develop products that will address COVID-19."

Dr. Gregory Brown, Memgen's CEO, stated, "We are honored and thrilled to have a professional of Dr. Monath's stature join our Scientific Advisory Board, and to welcome him to the Memgen SAB. His expertise and insight into vaccine development will be a powerful addition to the team as we advance our COVID-19 vaccine candidates into the clinic."

About Memgen

Memgen is developing new therapies to harness the power of the immune system to protect people from COVID-19 and other diseases, and to cure the most difficult cancers. The Company's pipeline products all utilize its proprietary CD40 ligand technology, MEM40, which has already been tested in people and has demonstrated the ability to elicit powerful, antigen-specific anti-tumor immune responses, while doing so safely.

Memgen's COVID-19 vaccine, MemVax, is designed to be used alone or in combination with other COVID-19 vaccines to generate a strong, durable immune response. MemVax is a highly specific immune stimulant that can work with COVID-19 antigens across a range of delivery approaches. Memgen has over 100,000 doses of MemVax ready to go into clinical trials, and an active file with the US FDA. Memgen plans to soon begin clinical trials of MemVax alone and in collaboration with other companies developing complementary COVID-19 vaccines.

The Company's lead cancer immunotherapy, MEM-288, was developed in collaboration with Moffitt Cancer Center. It is an oncolytic virus engineered to selectively target cancer cells and to supercharge the immune system through expression of two unique and powerful immune modulators: MEM40 and the powerful cytokine interferon beta. MEM-288 generates a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. Memgen expects to begin clinical testing with MEM-288 in advanced cancers this year.

In this press release, unless the context requires otherwise, "Memgen", the "Company," "Companies," "we," "our," and "us" refers to Memgen, Inc.

Investor Contact:

Gregory B. Brown, M.D.
(203) 940-3742
gbrown@memgenbio.com

For Memgen: Gregory B. Brown, M.D.
(203) 940-3742
gbrown@memgenbio.com

Related Images

SOURCE: Memgen

ReleaseID: 598887

VANCOUVER, BC / ACCESSWIRE / July 28, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt:8EC)("Empower" or the "Company") has filed today its unaudited interim condensed consolidated financial statements and related management's discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

"Our strong Q1 2020 performance is a direct reflection of the numerous changes and improvements from 2019, setting in motion a framework for sustained growth." said Steven McAuley, Chairman and CEO. "Our Sun Valley Health division started the year with record patient visits and now offers more diversified wellness services, adding new revenue sources and a more diversified business model."

Q1 2020 Highlights

5,717 patient visits generating total revenue of $789,135, compared to 1,198 patient visits generating $152,846 for Q1 2019.

Net loss of $524,208 or $0.00 per share, compared to $398,541 or $0.01 per share for Q1 2019, which was primarily driven by increased non-cash accretion expense.

Cash provided by operating activities was $13,864, compared to cash used by operating activities of $219,212 for Q1 2019.

Cash at March 31, 2020 of $131,808, compared to cash of $179,152 at December 31, 2019.

Recent Highlights Subsequent to Quarter End

Private Placement: Empower Clinics closes private placement of $653,000 CAD in April 2020 and $720,866 CAD in July 2020 to support growth initiatives.

Psychedelics Division: May 2020 Empower enters into a term sheet to acquire an interest in the global royalty rights of Dosed Movie, launches Dosed Wellness, a psychedelics brand, launches new dedicated website www.dosedwellness.com and adds new team members dedicated to the new brand.

COVID-19 Testing: April 2020 the Company launches a four-phase roll-out of COVID-19 testing in clinics and onsite for businesses.

Cannvas Education Platform: May 2020 Empower and EuroLife Brands complete definitive agreement for multi-year, multi-national licence of EurolIfe's cannvas.me web-based education technology platform to deliver brand, product, and industry knowledge to the market.

Financial Summary

$, except where noted

Three months ended March 31,

2020

2019

Patient visits (#)

5,717

1,198

Clinic Revenues

767,803

152,846

Direct Clinic Expenses

256,422

39,413

Loss from operations

(317,831)

(279,308)

Net loss

(524,208)

(398,541)

Net loss per share

(0.00)

(0.01)

Financial Performance

Clinic revenues for Q1 2020 and Q1 2019 were $767,803 and $152,846, respectively. This increase above prior year is attributable to the acquisition of Sun Valley and the addition of 5 clinics which drove an increase in patient count from 1,198 in Q1 2019 to 5,717 in Q1 2020.

Direct clinic expenses for Q1 2020 and Q1 2019 were $256,422 and $39,413, respectively. This increase above prior year is attributable to the increase in number of patient visits.

Net loss from operations for Q1 2020 and Q1 2019 were $317,831 and $279,308, respectively. This increase above prior year is primarily attributable to an increase in salaries and benefits with the acquisition of Sun Valley. This decrease was partially offset by an increase in clinic revenues with the acquisition of Sun Valley.

Net loss for Q1 2020 and Q1 2019 were $524,208 and $398,541, respectively. This increase over prior year is primarily attributable to non-cash accretion expense related to the convertible debentures.

During the three months ended March 31, 2020, the Company generated $13,864 in cash from operations after changes in non-cash working capital. The Company used $61,209 for payment of lease liabilities.

Please refer to the Company's unaudited condensed interim consolidated financial statements for the three months ended March 31, 2020 and 2019, and accompanying Management Discussion and Analysis for a full review of the operations.

About Empower

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer

CONTACTS:

Investors

Dustin Klein

Steven McAuley

Director

CEO

720-352-1398

604-789-2146

dustin@svmmjcc.com

s.mcauley@empowerclinics.com

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the direction and growth prospects of the Company, the expansion of the company's clinic and distribution network, the expected effect of the Vendors in their new roles with the Company, the effect on the lives of patients, the growth into a national brand, the effect of the Transaction, the diversification of the Company's business model, the potential appeal to shareholders, the growth of the Company's patient list and the effect thereof, the expected benefits for the company's patient base and customers, the release of the cash consideration, the release of Shares being held in escrow in connection with the Transaction and statements regarding the Company's proprietary product line "Sollievo". Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that the Company may not be able to expand, that the Transaction may not have the expected results, and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

ReleaseID: 599173

Since 2006, Knownhost has offered dependable and cost-effective web hosting solutions. Managed VPS hosting provided by Knownhost offers high-speed SSD performance, easy upgrades, and full root access plus control. Knownhost serves customers in more than 150 countries.

BIRMINGHAM, AL / ACCESSWIRE / July 28, 2020 / According to announcements released by Knownhost, VPS hosting provided by it helps businesses to impress visitors and the search engines. The different managed VPS hosting packages available cater to small and large businesses. They are a budget-friendly way to get ahead of the competition by offering a satisfying experience to visitors to the website.

The four packages on offer – Basic, Standard, Professional, and Premium – provide DDoS protection at no extra charges. Such security is extremely important for eCommerce sites that may otherwise be left vulnerable to financial losses and loss of brand value. Free SSL certification guarantees additional protection.

Customers can rely on instant upgrades without any impact on business. Migrating from one VPS plan to another or from VPS to dedicated hosting is achieved smoothly with no downtime or database migration issues. With 15 years in the industry and customers across 150 countries, Knownhost is a dependable web hosting provider with a reputation for excellent customer service. It operates hundreds of servers in four data centers in Europe and America.

The business has invested in high-quality hardware to ensure orderly and timely allocation of resources and maximum uptime. The enterprise-grade equipment is based on Dual Hex-Core Xeons that use RAID 10 storage arrays. A 30-day, money-back guarantee back all VPS hosting packages. Knownhost is managed by experienced professionals who have ensured a high level of service and customer satisfaction by utilizing high-bandwidth providers for dependable connectivity anywhere in the world.

For more information, go to https://www.knownhost.com/managed-vps.html

The managed VPS hosting plans at Knownhost offer everything SMBs and budding entrepreneurs need to set up a website best suited for achieving their business objectives. Customers can choose from cPanel, DirectAdmin, and other control panels of their choice. Businesses and agencies can also resell hosting and earn money.

Knownhost supports them with easy-to-use billing solutions. Partners can brand their servers with no mention of Knownhost. It's an attractive deal for agencies and marketers that offer hosting as a part of their product or service mix. Businesses that need superfast page loads can avail LiteSpeed and LSCache for a small monthly charge. The performance boost delivered helps customers go one up on the competition by ensuring a superior online experience to site visitors.

Backups are included as a part of the standard offering at no extra charge. These are set up from the beginning when the VPS is configured. The backups are run automatically, on schedule, and stored off-server for easy restoration of data should a catastrophic loss occur. Two dedicated IPv4 addresses are provided with every SSD VPS plan.

VPS hosting by Knownhost, both managed and unmanaged, can be used for running applications, hosting websites, SaaS applications, and much more. It's a value-for-money proposition. Customer support at Knownhost is available to help one decide the best VPS hosting for a given requirement.

Media Contact

Name: Daniel Pearson

Company: Knownhost

Phone: 1-866-332-9894

Address: 1625 Richard Arrington Jr Blvd S, Birmingham, AL 35205, United States

Email: sales@knownhost.com

Website: https://www.knownhost.com/managed-vps.html

SOURCE: Knownhost

ReleaseID: 599180

Australian-owned Sophie offers high-quality adjustable beds, designed to provide solutions to up to one in every two Australian adults suffering from poor quality sleep. With the many adverse effects of sleep deprivation, the company offers a Sleep Revolution.

BRISBANE, QUEENSLAND, AUSTRALIA / ACCESSWIRE / July 28, 2020 / Sleep Sophie is a line of high-quality products, including adjustable beds and pillows. The signature adjustability features include LED lighting with a back-up battery, pre-saved positions, and several memory buttons. USB connectivity and charging are built-in. Customers can depend on friendly and local technical support from the family company. Australian-owned Sophie offers high-quality adjustable beds, designed to provide solutions to up to one in every two Australian adults suffering from poor quality sleep.

Several benefits come from continued usage of the Sophie beds. These include natural sleep solutions for Whole Body Vibration Therapy to reduce the level of pain in the body, leading to better sleep solutions. For those suffering from edema, vibration therapy can reduce excess fluid, such as lymphatic or vascular edema fluid. Musculoskeletal pain can be reduced through the use of Premiere Plus adjustable beds. These features may assist in the mobilisation of joints. Vibration therapy may also help to benefit oxygen and blood flow in the circulatory system.

More details are available at https://www.sleepsophie.com.au/

The elegant appearance of the electrically adjustable base design is fully functional. Some of the outstanding features include customisable foot and head elevations, with memory positions that come pre-set or can be reprogrammed to suit the individual. The entire body can be treated to a luxurious vibration therapy. Under-bed LED lighting is both a safety feature and an aesthetic benefit. The beds include adjustable leg heights for convenience in bed-making and USB charging ports to keep cellphone available and charged. All these features combine to offer superior benefits for a fraction of the price of Sophie's largest competitors.

Improving sleep quality results in a more effective workday, as well as improved overall health and productivity. Spine, neck, and hip alignment can benefit from finding and remembering the right combination of head and foot elevations.

The Sophie team provides support staff for specific help. The company also provides free, fast delivery and installation when an adjustable bed is purchased directly from Sophie. Since late in 2018, Sophie engineers have been working to create improved sleep products that benefit health and mobility.

Media Contact

Name: Nathan Kerrins

Company: Sophie

Address: Australia

Phone: 1300 9 SLEEP (1300 975 337)

Email: admin@sleepsophie.com.au

SOURCE: Sophie

ReleaseID: 599179